Form 4: Maze Therapeutics CEO Sells Shares Under 10b5-1 Plan

Maze Therapeutics CEO Jason V. Coloma has reported the sale of company stock totaling over 32,500 shares, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jason V. Coloma, CEO of Maze Therapeutics, Inc., reported transactions involving the sale of common stock on May 22, 2026, and May 26, 2026.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on February 6, 2026, which is designed to comply with affirmative defense conditions for insider trading.
• On May 22, 2026, 4,504 shares were sold at a weighted average price of $26.00, and 2,478 shares were sold at a weighted average price of $26.00.
• On May 26, 2026, an additional 25,582 shares were sold at a weighted average price of $26.015.
• Following these transactions, Mr. Coloma's beneficial ownership of Maze Therapeutics common stock is reported as 376,569 shares held indirectly through the Coloma Family Trust and 28,523 shares held indirectly through The Coloma 2021 Irrevocable Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the CEO's sale of a notable number of shares, despite the transactions being compliant with a 10b5-1 plan.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies and regulatory compliance.
• The sales occurred at prices between $26.00 and $26.105, suggesting a stable or potentially increasing stock valuation at the time of the trades.

Negatives

• The CEO sold a significant number of shares (over 32,500), which could be interpreted negatively by the market, despite being executed under a plan.
• The total value of the shares sold is substantial, although specific aggregate figures are not provided in the filing.

Risks

• Market perception of insider selling, even if compliant with Rule 10b5-1, can negatively impact stock price.
• The company's future performance and stock valuation are subject to the inherent risks of the biotechnology sector, including clinical trial outcomes and regulatory approvals.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction. It solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the biotechnology sector as executives diversify holdings or manage personal finances. However, significant sales can sometimes signal a lack of immediate positive catalysts or a perceived overvaluation by management.

Stakeholder Impact

• Shareholders may view the CEO's stock sales with caution, potentially leading to short-term downward pressure on the stock price.
• Employees holding stock options or grants may be concerned about the CEO's confidence in the company's near-term prospects.

Next Steps

• Continued monitoring of Maze Therapeutics' stock performance and any future insider transactions.
• Analysis of the company's clinical development pipeline and regulatory milestones for potential catalysts.

Key Dates

Recommendation

The filing reports routine stock sales by the CEO under a pre-established 10b5-1 plan, which is a standard compliance measure. While insider selling can be a negative signal, the structured nature of the sale mitigates immediate concern. Without further information on the company's operational performance or future catalysts, a 'hold' recommendation is prudent, suggesting investors await more substantive news before making significant decisions.

Keywords

Maze Therapeutics, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, CEO, Beneficial Ownership, SEC Filing, Biotechnology